Source:http://linkedlifedata.com/resource/pubmed/id/18259035
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2008-3-21
|
| pubmed:abstractText |
Few studies have investigated the role of elevated lipoprotein-associated phospholipase A2 (Lp-PLA(2)) with stroke risk, and those that have are based on small numbers of strokes. No study has evaluated the effect of hormone therapy use on the association of Lp-PLA(2) and stroke. We assessed the relationship between Lp-PLA(2) and the risk of incident ischemic stroke in 929 stroke patients and 935 control subjects in the Hormones and Biomarkers Predicting Stroke Study, a nested case-control study from the Women's Health Initiative Observational Study. Mean (SD) levels of Lp-PLA(2) were significantly higher among case subjects (309.0 [97.1]) than control subjects (296.3 [87.3]; P<0.01). Odds ratio for ischemic stroke for the highest quartile of Lp-PLA(2), compared with lowest, controlling for multiple covariates, was 1.08 (95% CI: 0.75 to 1.55). However, among 1137 nonusers of hormone therapy at baseline, the corresponding odds ratio was 1.55 (95% CI: 1.05 to 2.28),whereas there was no significant association among 737 hormone users (odds ratio: 0.70; 95% CI: 0.42 to 1.17; P for interaction=0.055). Moreover, among nonhormone users, women with high C-reactive protein and high Lp-PLA2 had more than twice the risk of stroke (odds ratio: 2.26; 95% CI: 1.55 to 3.35) compared with women low levels in both biomarkers. Furthermore, different stroke cases were identified as high risk by Lp-PLA(2) rather than by C-reactive protein. Lp-PLA(2) was associated with incident ischemic stroke independently of C-reactive protein and traditional cardiovascular risk factors among nonusers of hormone therapy with highest risk in those who had both high C-reactive protein and high Lp-PLA(2).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1524-4563
|
| pubmed:author |
pubmed-author:AllisonMatthew AMA,
pubmed-author:BairdAlison EAE,
pubmed-author:BergerJeffrey SJS,
pubmed-author:HendrixSusan LSL,
pubmed-author:HsiaJudithJ,
pubmed-author:KaplanRobert CRC,
pubmed-author:KooperbergCharlesC,
pubmed-author:KullerLewis HLH,
pubmed-author:MansonJoAnn EJE,
pubmed-author:McGinnAileen PAP,
pubmed-author:Wassertheil-SmollerSylviaS
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
51
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1115-22
|
| pubmed:meshHeading |
pubmed-meshheading:18259035-1-Alkyl-2-acetylglycerophosphocholine Esterase,
pubmed-meshheading:18259035-Aged,
pubmed-meshheading:18259035-Biological Markers,
pubmed-meshheading:18259035-Brain Ischemia,
pubmed-meshheading:18259035-C-Reactive Protein,
pubmed-meshheading:18259035-Case-Control Studies,
pubmed-meshheading:18259035-Estrogen Replacement Therapy,
pubmed-meshheading:18259035-Female,
pubmed-meshheading:18259035-Follow-Up Studies,
pubmed-meshheading:18259035-Humans,
pubmed-meshheading:18259035-Middle Aged,
pubmed-meshheading:18259035-Postmenopause,
pubmed-meshheading:18259035-Predictive Value of Tests,
pubmed-meshheading:18259035-Risk Factors,
pubmed-meshheading:18259035-Stroke,
pubmed-meshheading:18259035-Women's Health
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women.
|
| pubmed:affiliation |
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA. smoller@aecom.yu.edu
|
| pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|